Clinical use of omega-3 fatty acids in migraine: A narrative review.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
16 Oct 2020
16 Oct 2020
Historique:
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
5
11
2020
Statut:
ppublish
Résumé
Omega-3 fatty acids (FAs) can produce several beneficial effects and are commonly used for the treatment of migraine symptoms. Although current therapeutic measures for migraine included pharmacological therapies, dietary supplements, and herbal ingredients, dietary patterns, acupuncture, relaxation techniques, biofeedback, and psychotherapy, omega-3 FAs therapeutic role seems to be obtained through the inhibition or reduction of the release of inflammatory cytokines. The present review aims to provide updated information about the effects of omega-3 FAs in migraine treatment, investigating their clinical effects alone or in combination with other substances. Bibliographic research was conducted by examining scientific literature from January 2000 until January 31, 2020. Ten clinical studies were included in the review. Quality assessment of randomized controlled trials was performed by using the JADAD scale. Clinical studies methodology is not always of good quality and results show moderate evidence concerning the therapeutic role of omega-3 FAs in migraine. Further clinical trials are necessary to implement the knowledge concerning the use of omega-3 fatty acids in the treatment of migraine.
Sections du résumé
BACKGROUND
BACKGROUND
Omega-3 fatty acids (FAs) can produce several beneficial effects and are commonly used for the treatment of migraine symptoms. Although current therapeutic measures for migraine included pharmacological therapies, dietary supplements, and herbal ingredients, dietary patterns, acupuncture, relaxation techniques, biofeedback, and psychotherapy, omega-3 FAs therapeutic role seems to be obtained through the inhibition or reduction of the release of inflammatory cytokines. The present review aims to provide updated information about the effects of omega-3 FAs in migraine treatment, investigating their clinical effects alone or in combination with other substances.
METHODS
METHODS
Bibliographic research was conducted by examining scientific literature from January 2000 until January 31, 2020. Ten clinical studies were included in the review. Quality assessment of randomized controlled trials was performed by using the JADAD scale.
RESULTS
RESULTS
Clinical studies methodology is not always of good quality and results show moderate evidence concerning the therapeutic role of omega-3 FAs in migraine.
CONCLUSION
CONCLUSIONS
Further clinical trials are necessary to implement the knowledge concerning the use of omega-3 fatty acids in the treatment of migraine.
Identifiants
pubmed: 33080672
doi: 10.1097/MD.0000000000022253
pii: 00005792-202010160-00005
pmc: PMC7572026
doi:
Substances chimiques
Fatty Acids, Omega-3
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e22253Références
Tajmirriahi M, Sohelipour M, Basiri K, et al. The effects of sodium valproate with fish oil supplementation or alone in migraine prevention: a randomized single-blind clinical trial. Iran J Neurol 2012;11:21–4.
Saravanan P, Davidson NC. The role of omega-3 fatty acids in primary prevention of coronary artery disease and in atrial fibrillation is controversial. J Am Coll Cardiol 2010;55:410–1. (author reply 411–2).
Wall R, Ross RP, Fitzgerald L GF, et al. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 2010;68:280–9.
Lauritzen I, Blondeau N, Heurteaux C, et al. Polyunsaturated fatty acids are potent neuroprotectors. EMBO J 2000;19:1784–93.
Alemany R, Perona JS, Sánchez-Dominguez JM, et al. G protein-coupled receptor systems and their lipid environment in health disorders during aging. Biochim Biophys Acta 2007;1768:964–75.
Bazan NG. Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr Opin Clin Nutr Metab Care 2007;10:136–41.
Kuda O, Brezinova M, Rombaldova M, et al. Docosahexaenoic acid-derived fatty acid esters of hydroxy fatty acids (FAHFAs) with anti-inflammatory properties. Diabetes 2016;65:2580–90.
Forman MS, Lal D, Zhang B, et al. Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. J Neurosci 2005;25:3539–50.
Hasadsri L, Wang BH, Lee JV, et al. Omega-3 fatty acids as a putative treatment for traumatic brain injury. J Neurotrauma 2013;30:897–906.
Abdelmoaty S, Wigerblad G, Bas DB, et al. Spinal actions of lipoxin A4 and 17(R)-resolvin D1 attenuate inflammation-induced mechanical hypersensitivity and spinal TNF release. PLoS One 2014;8:e75543doi: 10.1371/journal.pone.0075543.
doi: 10.1371/journal.pone.0075543
Brenna JT, Carlson SE. Docosahexaenoic acid and human brain development: evidence that a dietary supply is needed for optimal development. J Hum Evol 2014;77:99–106.
Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002;21:495–505.
Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc 2002;61:345–55.
Ramsden CE, Faurot KR, Zamora D, et al. Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial. Pain 2013;154:2441–51.
Harel Z, Gascon G, Riggs S, et al. Supplementation with omega-3 polyunsaturated fatty acids in the management of recurrent migraines in adolescents. J Adolesc Health 2002;31:154–61.
Sastry PS. Lipids of nervous tissue: composition and metabolism. Prog Lipid Res 1985;24:69–176.
Soveyd N, Abdolahi M, Bitarafan S, et al. Molecular mechanisms of omega-3 fatty acids in the migraine headache. Iran J Neurol 2017;16:210–7.
Sekiya M, Yahagi N, Matsuzaka T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003;38:1529–39.
Richardson AJ, Puri BK. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties, Prog. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:233–9.
Jicha GA, Markesbery WR. Omega-3 fatty acids: potential role in the management of early Alzheimer's disease. Clin Interv Aging 2010;5:45–61.
Logan AC. Neurobehavioral aspects of omega-3 fatty acids: possible mechanisms and therapeutic value inmajor depression. Altern Med Rev 2003;8:410–25.
Palacios-Pelaez R, Lukiw WJ, Bazan NG. Omega-3 essential fatty acids modulate initiation and progression of neurodegenerative disease. Mol Neurobiol 2010;41:367–74.
Norouzi Javidan A, Sabour H, Latifi S, et al. Does consumption of polyunsaturated fatty acids influence on neurorehabilitation in traumatic spinal cord-injured individuals? A double-blinded clinical trial. Spinal Cord 2014;52:378–82.
Michael-Titus AT. Omega-3 fatty acids: their neuroprotective and regenerative potential in traumatic neurological injury. Clin Lipidology 2009;4:343–53.
Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006;29:2365–70.
Ko GD, Nowacki NB, Arseneau L, et al. Omega-3 fatty acids for neuropathic pain: case series. Clin J Pain 2010;26:168–72.
Ramsden CE, Faurot KR, Zamora D, et al. Targeted alterations in dietary n-3 and n-6 fatty acids improve life functioning and reduce psychological distress among patients with chronic headache: a secondary analysis of a randomized trial. Pain 2015;156:587–96.
Tietjen GE. Migraine as a systemic vasculopathy. Cephalalgia 2009;29:987–96.
Andreou AP, Edvinsson L. Mechanisms of migraine as a chronic evolutive condition. J Headache Pain 2019;20:117doi:10.1186/s10194-019-1066-0.
doi: 10.1186/s10194-019-1066-0
Abdolahi M, Mohammadzadeh Honarvar N, Tafakhori A, et al. The combined effects of omega3 fatty acids and nanocurcumin supplementation on gene expression and serum levels of some inflammatory and endothelial factors in migraine patients: study protocol for a randomized controlled trial. Int J Pharm Sci Invent 2016;5:42–6.
Mulder EJ, Van Baal C, Gaist D, et al. Genetic and environmental influences on migraine: a twin study across six countries. Twin Res 2003;6:422–31.
Malhotra R. Understanding migraine: potential role of neurogenic inflammation. Ann Indian Acad Neurol 2016;19:175–82.
Fidan I, Yüksel S, Ýmir T, et al. The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J Neuroimmunol 2006;171:184–8.
Longoni M, Ferrarese C. Inflammation and excitotoxicity: role in migraine pathogenesis. Neurol Sci 2006;27: (suppl): S107–10.
D’Andrea G, Leon A. Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond. Neurol Sci 2010;31: (suppl): S1–7.
Hamed SA. The vascular risk associations with migraine: relation to migraine susceptibility and progression. Atherosclerosis 2009;205:15–22.
DosSantos MF, Holanda-Afonso RC, Lima RL, et al. The role of the blood-brain barrier in the development and treatment of migraine and other pain disorders. Front Cell Neurosci 2014;8:302doi:10.3389/fncel.2014.00302.
doi: 10.3389/fncel.2014.00302
Saegusa H, Tanabe T. N-typevoltage-dependentCa2+ channel in non excitable microglial cells in mice is involved in the pathophysiology of neuropathic pain. Biochem Biophys Res Commun 2014;450:142–7.
Abdolahi M, Jafarieh A, Sarraf P, et al. The neuromodulatory effects of ω-3 fatty acids and nano-curcumin on the COX-2/iNOS network in migraines: A Clinical Trial Study from Gene Expression to Clinical Symptoms. Endocr Metab Immune Disord Drug Targets 2019;19:874–84.
Haut SR, Bigal ME, Lipton RB. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol 2006;5:148–57.
Stovner Lj, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193–210.
Ayatollahi Seyyed Mohammad T, Sahebi L, BorhaniHaghighi A. Epidemiologic and clinical characteristics of migraine and tension-type headaches among hospitals staffs of Shiraz (Iran). ActaMedicaIranica 2009;47:115–20.
Lewis D, Winner P, Saper J, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics 2009;123:924–34.
Lewis DW, Winner P. The pharmacological treatment options for pediatric migraine: an evidence-based appraisal. NeuroRx 2006;3:181–91.
Pothmann R, Danesch U. Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache 2005;45:196–203.
Larsson B. The role of psychosocial, health behavioral and medical factors in adolescent headache. Dev Med Child Neurol 1988;30:616–25.
Gerring ZF, Powell JE, Montgomery GW, et al. Genome-wide analysis of blood gene expression in migraine implicates immune-inflammatory pathways. Cephalalgia 2018;38:292–303.
Levy D. Migraine pain and nociceptor activation – where do we stand? Headache 2010;50:909–16.
Vigh L, Escribá PV, Sonnleitner A, et al. The significance of lipid composition for membrane activity: new concepts and ways of assessing function. Prog Lipid Res 2005;44:303–44.
Casas J, Ibarguren M, Álvarez R, et al. G protein-membrane interactions II: Effect of G protein-linked lipids on membrane structure and G protein-membrane interactions. Biochim Biophys Acta Biomembr 2017;1859:1526–35.
Escribá PV, Wedegaertner PB, Goñi FM, et al. Lipid-protein interactions in GPCR-associated signaling. Biochim Biophys Acta 2007;1768:836–52.
Stender S, Dyerberg J. Influence of trans fatty acids on health. Ann Nutr Metab 2004;48:61–6.
Diep QN, Touyz RM, Schiffrin EL. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension 2000;36:851–5.
Zúñiga J, Cancino M, Medina F, et al. N-3 PUFA supplementation triggers PPAR-α activation and PPAR-α/NF-κB interaction: anti-inflammatory implications in liver ischemia-reperfusion injury. PLoS One 2011;6:e28502doi:10.1371/journal.pone.0028502.
doi: 10.1371/journal.pone.0028502
Chiang N, Serhan CN. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol Aspects Med 2017;58:114–29.
Clària J, Nguyen BT, Madenci AL, et al. Diversity of lipid mediators in human adipose tissue depots. Am J Physiol Cell Physiol 2013;304:C1141–9.
Galano JM, Lee JC, Gladine C, et al. Non-enzymatic cyclic oxygenated metabolites of adrenic, docosahexaenoic, eicosapentaenoic and α-linolenic acids; bioactivities and potential use as biomarkers. Biochim Biophys Acta 2015;1851:446–55.
Kuda O. Bioactive metabolites of docosahexaenoic acid. Biochimie 2017;136:12–20.
Calder PC. Long chain fatty acids and gene expression in inflammation and immunity. Curr Opin Clin Nutr Metab Care 2013;16:425–33.
Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83: (6 suppl): 1505S–19S.
Abdolahi M, Tafakhori A, Togha M, et al. The synergistic effects of omega-3 fatty acids and nano-curcumin supplementation on tumor necrosis factor (TNF)-alpha gene expression and serum level in migraine patients. Immunogenetics 2017;69:371–8.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700doi: 10.1136/bmj.b2700.
doi: 10.1136/bmj.b2700
Sun-Edelstein C, Mauskop A. Foods and supplements in the management of migraine headaches. Clin J Pain 2009;25:446–52.
Damen L, Bruijn JK, Verhagen AP, et al. Symptomatic treatment of migraine in children: a systematic review of medication trials. Pediatrics 2005;116:e295–302.
Pradalier A, Bakouche P, Baudesson G, et al. Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: a double-blind study versus placebo. Cephalalgia 2001;21:818–22.
Soares AA, Louçana PMC, Nasi EP, et al. A double- blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA ω-3) for the prevention of migraine in chronic migraine patients using amitriptyline. Nutr Neurosci 2018;21:219–23.
Brietzke E, Mansur RB, Grassi-Oliveira R, et al. Inflammatory cytokines as an underlying mechanism of the comorbidity between bipolar disorder and migraine. Med Hypotheses 2012;78:601–5.
Tonekaboni SH, Ghazavi A, Fayyazi A, et al. Prophylaxis of childhood migraine: topiramate versus propranolol. Iran J Child Neurol 2013;7:9–14. winter.
Olness K, MacDonald JT, Uden DL. Comparison of self-hypnosis and propranolol in the treatment of juvenile classic migraine. Pediatrics 1987;79:593–7.
Ziegler DK, Hurwitz A, Preskorn S, et al. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. Arch Neurol 1993;50:825–30.
Fayyazi A, Khajeh A, Ghazavi A, et al. Omega 3 in childhood migraines: a double blind randomized clinical trial. Iran J Child Neurol 2016;10:9–13. Winter.
Saw CLL, Huang Y, Kong A-N. Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem Pharmacol 2010;79:421–30.
Mittal N, Joshi R, Hota D, et al. Evaluation of antihyperalgesic effect of curcumin on formalin-induced orofacial pain in rat. Phytother Res 2009;23:507–12.
Abdolahi M, Sarraf P, Javanbakht MH, et al. A Novel Combination of ω-3 fatty acids and nano-curcumin modulates interleukin-6 gene expression and high sensitivity c-reactive protein serum levels in patients with migraine: a randomized Clinical Trial Study. CNS Neurol Disord Drug Targets 2018;17:430–8.
Ramos TN, Bullard DC, Barnum SR. ICAM-1: isoforms and phenotypes. J Immunol 2014;192:4469–74.
Soveyd N, Abdolahi M, Djalali M, et al. The combined effects of ω -3 fatty acids and nano-curcumin supplementation on intercellular adhesion molecule-1 (ICAM-1) gene expression and serum levels in migraine patients. CNS Neurol Disord Drug Targets 2018;16:1120–6.